TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Triprolidine Hydrochloride And Pseudoephedrine Hydrochloride, and what generic alternatives are available?

Triprolidine Hydrochloride And Pseudoephedrine Hydrochloride is a drug marketed by Ivax Sub Teva Pharms and Superpharm and is included in two NDAs.

The generic ingredient in TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE is pseudoephedrine hydrochloride; triprolidine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the pseudoephedrine hydrochloride; triprolidine hydrochloride profile page.

Summary for TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	4
Patent Applications:	8
DailyMed Link:	TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE at DailyMed

US Patents and Regulatory Information for TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Sub Teva Pharms	TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride; triprolidine hydrochloride	TABLET;ORAL	085273-001	Dec 12, 1984		DISCN	No	No
Superpharm	TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride; triprolidine hydrochloride	TABLET;ORAL	088578-001	Feb 21, 1985		DISCN	No	No

Triprolidine Hydrochloride and Pseudoephedrine Hydrochloride Market Dynamics and Financial Trajectory

Last updated: August 3, 2026

Triprolidine hydrochloride and pseudoephedrine hydrochloride is a mature, low-cost oral antihistamine-decongestant combination marketed primarily through generic, store-brand, and legacy branded products such as Actifed. Its commercial outlook is driven by seasonal respiratory demand, pharmacy-channel access, pseudoephedrine purchase restrictions, and price competition rather than by patent-protected innovation.

The combination has limited prospects for pharmaceutical revenue growth. Value is concentrated in manufacturing efficiency, retail distribution, private-label contracting, and compliant supply of pseudoephedrine products.

What is the market position of triprolidine and pseudoephedrine?

Triprolidine is a first-generation H1 antihistamine. Pseudoephedrine is an oral sympathomimetic decongestant. The combination targets temporary relief of nasal congestion, runny nose, sneezing, and related cold symptoms.

Attribute	Market assessment
Product category	OTC combination cold medicine
Typical dosage form	Immediate-release tablet, caplet, or oral liquid
Common tablet strength	Triprolidine HCl 2.5 mg plus pseudoephedrine HCl 60 mg
Primary channels	Pharmacies, mass merchants, grocery stores, e-commerce, institutional retail
Prescription status	Generally OTC, subject to pseudoephedrine sales controls
Competitive set	Cetirizine-pseudoephedrine, loratadine-pseudoephedrine, brompheniramine-pseudoephedrine, phenylephrine combinations, standalone pseudoephedrine
Patent dependence	Low
Biosimilar exposure	None
Commercial maturity	Mature and declining in branded value; stable in generic and private-label volume

The product competes in a broad cold-and-allergy market rather than in a protected specialty-drug segment. Consumers can substitute among antihistamines, oral decongestants, nasal sprays, cough-and-cold combinations, and non-drug treatments.

What is the FDA regulatory status of the combination?

The combination is generally regulated as an OTC drug rather than as a newly developed prescription product. FDA’s OTC framework permits certain active ingredients and combinations when they comply with applicable monograph conditions, labeling requirements, dosage limits, and manufacturing standards. The relevant regulatory framework includes the OTC monograph system for antihistamines and oral nasal decongestants under 21 C.F.R. Part 341.[1]

Under the FDA’s post-CARES Act OTC monograph system, applicable monograph drugs are governed through administrative orders rather than the former monograph rulemaking structure.[2] Products marketed under an OTC monograph must comply with the applicable monograph and general FDA requirements. Products outside the monograph pathway may require an approved drug application.

How do pseudoephedrine restrictions affect the market?

Pseudoephedrine is subject to federal retail controls under the Combat Methamphetamine Epidemic Act. Retail sellers must place regulated pseudoephedrine products behind the counter or in a locked area, verify purchaser identity, maintain transaction records, and enforce daily and monthly quantity limits.[3]

These controls create four commercial effects:

1. They reduce impulse purchases and increase pharmacy-channel dependence.
2. They raise compliance and inventory-management costs.
3. They limit some e-commerce and unattended retail models.
4. They favor established distributors and retailers with compliant point-of-sale systems.

State-level requirements can add electronic tracking, purchase restrictions, or other controls. These requirements affect distribution economics more than they affect the underlying product formulation.

When does triprolidine-pseudoephedrine lose exclusivity?

The core combination is an old, off-patent medicine. Its commercial exclusivity has effectively expired in the United States. The principal competitive barriers are regulatory compliance, manufacturing validation, supply reliability, retailer access, and pseudoephedrine controls.

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
New formulation exclusivity	No material current exclusivity identified
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No commercially relevant current period identified
Biosimilar exclusivity	Not applicable
Core composition patent protection	Not a meaningful current barrier
Generic substitution risk	High

No active patent estate is publicly associated with the mature triprolidine-pseudoephedrine combination that would normally delay ordinary generic or private-label competition. A company commercializing a specific product could still hold patents on a newer delivery system, packaging configuration, manufacturing process, or formulation, but those rights would not generally protect the conventional immediate-release combination.

What patents protect triprolidine hydrochloride and pseudoephedrine hydrochloride products?

The core active ingredients and conventional immediate-release combination are not dependent on a current composition-of-matter patent. The relevant IP analysis is therefore product-specific.

Potentially relevant rights can include:

• Modified-release tablets or multiparticulate systems.
• Taste-masked or pediatric oral liquids.
• Abuse-deterrent or tamper-resistant packaging.
• Novel excipient systems.
• Manufacturing processes that improve stability or content uniformity.
• Combination products using a different antihistamine or decongestant ratio.
• Trademarks and trade dress for legacy branded products.

These rights usually have narrower commercial value than a new chemical entity patent. A process patent may be designed around. A packaging patent may not prevent substitution with a conventional generic. A trademark protects brand identity but does not prevent competing products from using the same active ingredients.

What is the Orange Book status of triprolidine-pseudoephedrine?

The Orange Book is most relevant to approved prescription and certain approved drug applications. Conventional OTC monograph products generally do not receive Orange Book patent-listing protection in the same way as patented prescription products.

The commercial implication is direct: a generic or private-label manufacturer generally does not need to overcome a major Orange Book patent dispute before selling a compliant OTC monograph product. If a particular branded combination is marketed under an approved NDA rather than solely under the OTC monograph pathway, its application-specific listing must be reviewed in Drugs@FDA and the current Orange Book.[4]

For the mature conventional product, Orange Book-based Paragraph IV litigation is unlikely to be the main entry issue.

Are there Paragraph IV challenges or patent litigation?

No major, current Paragraph IV litigation is generally associated with the conventional triprolidine-pseudoephedrine combination. Paragraph IV litigation is more relevant to prescription products with listed patents and abbreviated new drug applications. A conventional OTC product marketed under an applicable monograph does not usually generate the same patent-certification pathway.

The principal legal risks are more likely to involve:

• FDA compliance actions.
• Labeling disputes.
• Trademark infringement.
• False advertising or comparative-marketing claims.
• Product liability.
• Manufacturing-quality failures.
• Distributor or retailer contract disputes.
• State restrictions affecting pseudoephedrine sales.

A company assessing an acquisition or launch should distinguish between rights covering the active ingredients and rights covering a specific brand, package, liquid formulation, or delivery technology.

How strong is the patent estate for this drug combination?

The patent estate is weak for conventional immediate-release tablets and liquids. The product’s defensibility depends on execution rather than exclusivity.

Defensibility factor	Strength
Active-ingredient patent protection	Very low
Conventional formulation protection	Very low
Regulatory complexity	Moderate
Pseudoephedrine compliance burden	Moderate to high
Manufacturing barriers	Low to moderate
Retail access barriers	Moderate
Brand loyalty	Low to moderate
Private-label substitution risk	High
Supply-chain differentiation	Moderate

Manufacturing is relatively accessible for established oral solid-dose producers. The more meaningful operational barriers are controlled pseudoephedrine sourcing, accurate assay and content uniformity, stability, packaging compliance, lot release, and retailer onboarding.

What is the competitive landscape?

The combination competes against both therapeutic substitutes and different formulations.

Direct competitors

Direct competitors include generic and branded products containing:

• Triprolidine plus pseudoephedrine.
• Brompheniramine plus pseudoephedrine.
• Chlorpheniramine plus pseudoephedrine.
• Antihistamine-decongestant combinations sold under store brands.

Functional substitutes

Functional substitutes include:

• Pseudoephedrine alone.
• Cetirizine-pseudoephedrine extended-release products.
• Loratadine-pseudoephedrine extended-release products.
• Intranasal corticosteroids for allergic rhinitis.
• Intranasal antihistamines.
• Saline sprays and other nonprescription products.
• Phenylephrine products, despite weaker efficacy concerns for oral formulations.

Pseudoephedrine remains commercially important because it has a stronger established decongestant profile than oral phenylephrine. FDA has proposed removing oral phenylephrine from the OTC monograph after concluding that available data do not support its effectiveness at the permitted dose.[5] That action can increase attention toward pseudoephedrine, but purchase restrictions limit the extent of any volume shift.

What is the financial trajectory?

Public financial reporting generally does not isolate revenue for triprolidine-pseudoephedrine products. Branded manufacturers typically report broader consumer-health categories, while generic manufacturers aggregate products across portfolios. A precise product-level revenue forecast therefore cannot be derived from public company filings.

The financial trajectory is best characterized as follows:

Period	Expected commercial pattern
Historical period	Branded product erosion as generic and store-brand alternatives expanded
Current mature phase	Low unit growth, seasonal demand, thin margins, and heavy retail price competition
Near-term outlook	Stable to modestly declining value; episodic volume gains during severe cold seasons
Long-term outlook	Continued migration toward private label, standalone ingredients, and newer allergy-decongestant combinations

Revenue drivers

Revenue is affected by:

• Winter respiratory-virus activity.
• Allergy-season intensity.
• Retail inventory levels.
• Pseudoephedrine purchase restrictions.
• Product availability and shortages.
• Private-label placement.
• Consumer movement toward non-drowsy antihistamines.
• Retail price promotions.
• Formulation preferences, including tablets versus liquids.

Margin profile

The conventional product is likely to have low gross margins relative to patented medicines. Pricing power is limited because buyers can switch among multiple suppliers with similar active ingredients. Margin performance depends on scale, procurement, manufacturing utilization, packaging cost, and retailer terms.

A branded product can retain a price premium through recognition and distribution, but that premium is vulnerable to store-brand substitution. Generic suppliers can earn acceptable returns when they have efficient plants, stable pseudoephedrine procurement, and high-volume contracts.

What generic launch risks exist?

Generic launch risk is regulatory and commercial rather than patent-driven.

A prospective manufacturer must manage:

1. Compliance with the applicable OTC monograph or approved application pathway.
2. Federal and state pseudoephedrine controls.
3. Controlled inventory records and retail verification systems.
4. cGMP compliance under 21 C.F.R. Parts 210 and 211.[6]
5. Stability, dissolution, assay, and content-uniformity requirements.
6. Child-resistant and tamper-evident packaging where applicable.
7. Labeling restrictions for age groups, warnings, and maximum daily use.
8. Retailer and distributor qualification.

The largest commercial risk is not failure to enter. It is entering a commoditized market without sufficient volume, retailer access, or cost advantage.

What licensing deals affect the product?

Licensing opportunities are limited because the active ingredients are old and widely available. Transactions are more likely to involve:

• Acquisition of a legacy consumer-health brand.
• Private-label supply agreements.
• Contract manufacturing.
• Regional distribution rights.
• Portfolio transfers between OTC companies.
• Licensing of a modified-release or pediatric formulation.

A license covering the conventional active ingredients would have little strategic value unless it also included a strong brand, exclusive retail placement, protected formulation, or manufacturing advantage.

What geographic markets offer the strongest opportunity?

The United States remains commercially significant because pseudoephedrine has an established OTC role, but the regulatory burden is unusually high. Canada, Europe, and other markets have different rules for pseudoephedrine availability, antihistamine combinations, labeling, and pharmacy distribution.

Geographic expansion cannot rely on a single global regulatory strategy. Each market requires review of:

• Permitted active ingredients.
• Maximum strengths and daily doses.
• Prescription versus OTC classification.
• Pharmacist-only restrictions.
• Combination-product rules.
• Local warnings and package sizes.
• Import and controlled-substance requirements.

The product’s strongest opportunity is usually in markets where oral pseudoephedrine remains available without prescription and where consumers continue to purchase combination cold remedies.

How does it compare with newer antihistamine-decongestant products?

Product type	Main advantage	Main disadvantage	Commercial position
Triprolidine-pseudoephedrine	Established efficacy and low cost	Sedation and mature brand profile	Low-cost legacy segment
Cetirizine-pseudoephedrine	Less sedating antihistamine profile	Higher price and extended-release complexity	Stronger allergy positioning
Loratadine-pseudoephedrine	Non-sedating positioning	Higher price and patent-history complexity for some products	Established branded/generic segment
Pseudoephedrine alone	Simple product and lower formulation cost	Does not address histamine symptoms	Durable core decongestant category
Phenylephrine combinations	Broad retail availability	FDA effectiveness concerns for oral use	Regulatory and demand pressure

Triprolidine-pseudoephedrine is most competitive when price and broad cold-symptom coverage matter more than non-sedating positioning.

Key Takeaways

• Triprolidine hydrochloride and pseudoephedrine hydrochloride is a mature OTC combination with limited patent-based protection.
• The core product is effectively off-patent, and conventional generic entry is not normally blocked by a meaningful active patent estate.
• Orange Book and Paragraph IV issues are less important than OTC monograph compliance and pseudoephedrine retail controls.
• Revenue is fragmented and generally not disclosed at the product level.
• Branded revenue is likely to continue shifting toward generic, store-brand, and private-label products.
• The financial profile is low-growth and margin-sensitive, with seasonal volume spikes.
• The strongest commercial advantages are manufacturing scale, regulatory compliance, supply reliability, and retailer access.
• No biosimilar risk exists because this is a small-molecule OTC combination.
• Modified-release, pediatric, packaging, and branded formulations may create narrower commercial differentiation, but they do not materially protect the conventional product.
• FDA scrutiny of oral phenylephrine could support pseudoephedrine demand, although purchase restrictions limit the potential volume benefit.

FAQs

Is triprolidine-pseudoephedrine still commercially attractive?

It is attractive as a low-cost, high-volume portfolio product for manufacturers with established OTC distribution. It is less attractive as a standalone branded growth product because price competition and substitution are intense.

Does pseudoephedrine require a prescription in the United States?

Generally, no. It is usually sold behind the counter or from a locked area, with identity verification, transaction records, and quantity limits under federal law and additional state requirements.

Can a company launch a generic triprolidine-pseudoephedrine product without a Paragraph IV filing?

For a product marketed under the applicable OTC monograph pathway, the launch generally does not follow the same ANDA patent-certification process as a patented prescription drug. The exact pathway depends on the product’s regulatory status and formulation.

Is triprolidine-pseudoephedrine more effective than phenylephrine combinations?

Pseudoephedrine has a stronger established clinical basis as an oral decongestant. FDA has proposed removing oral phenylephrine from the OTC monograph because available data did not support effectiveness at the permitted dose.[5]

What is the principal investment risk for this product category?

The main risk is commoditization. A manufacturer can face declining prices, retailer concentration, seasonal demand volatility, pseudoephedrine compliance costs, and substitution by newer non-sedating allergy products.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-reform

3. U.S. Drug Enforcement Administration. (2024). Combat methamphetamine epidemic act requirements. https://www.deadiversion.usdoj.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda

5. U.S. Food and Drug Administration. (2023). FDA proposes order to remove oral phenylephrine from OTC monograph. https://www.fda.gov/drugs/drug-safety-and-availability

6. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210